Managed Healthcare Connect Presents Details of New PHE RA Study

Christina Vogt with Managed Healthcare Connect recently provided a breakdown and analysis of a new PHE study on the impact of ACPA status on patient costs associated with rheumatoid arthritis.

Published in the Journal of Managed Care Pharmacy, the study demonstrated that patients with rheumatoid arthritis (RA) who are anticitrullinated protein antibodies (ACPA)-positive face a greater economic burden than those who are ACPA-negative.

To read the article, please click here.

To read the study as it appears in the Journal of Managed Care Pharmacy, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.